Blog
RSS FeedPosted by Michael Wonder on 09 Dec 2017
NICE nods for AbbVie in hepatitis C and Novartis in lung cancer
8 December 2017 - NICE has published new draft guidance for Novartis' Zykadia and AbbVie's Maviret. ...
Posted by Michael Wonder on 08 Dec 2017
New deal will give people with kidney cancer another treatment option
8 December 2017 - People with advanced kidney cancer are set to benefit from a new treatment, after NICE has said ...
Posted by Michael Wonder on 07 Dec 2017
Roche’s Tecentriq available via CDF
7 December 2017 - Roche’s Tecentriq will be available on the NHS in England via the Cancer Drugs Fund for ...
Posted by Michael Wonder on 07 Dec 2017
NICE launches PRIMA to health-check economic models
7 December 2017 - NICE Scientific Advice offers a new service for healthcare product developers to check the quality of their ...
Posted by Michael Wonder on 05 Dec 2017
Novartis and Roche get NICE rejections
5 December 2017 - There was disappointing news today for Swiss pharma giants Novartis and Roche when the UK’s NICE ...
Posted by Michael Wonder on 04 Dec 2017
Brexit may mean British patients have to wait longer for life-saving drugs with the NHS forced to shell out more for them, pharmaceutical bosses warn
3 December 2017 - Pharmaceutical boss Mark Hicken was addressing the House of Lords last week. ...
Posted by Michael Wonder on 02 Dec 2017
Accelerated access to new drugs and technologies
22 November 2017 - UK government’s proposed scheme is unlikely to improve patient outcomes. ...
Posted by Michael Wonder on 27 Nov 2017
NICE no for Halaven in new indication
27 November 2017 - A lack of clinical evidence proving its effectiveness has led NICE to publish draft guidance refusing ...
Posted by Michael Wonder on 27 Nov 2017
Kidney disease drug recommended by NICE 'may do more harm than good
24 November 2017 - Little evidence that phosphate binders improve patient wellbeing, warn experts, while one type may contribute to increased ...
Posted by Michael Wonder on 27 Nov 2017
Merck invited to submit a CDF proposal for Merkel cell cancer drug
27 November 2017 - NICE has asked Merck to submit a Cancer Drugs Fund proposal for an immunotherapy called avelumab. ...
Posted by Michael Wonder on 25 Nov 2017
How to avoid giving the right answers to the wrong questions: the need for integrated assessments of complex health technologies
23 November 2017 - Health technologies are becoming increasingly complex and contemporary health technology assessment is only partly equipped to address ...
Posted by Michael Wonder on 25 Nov 2017
Reflections on the NICE decision to reject patient production losses
20 November 2017 - Patient production losses occur when individuals’ capacities to work, whether paid or unpaid, are impaired by illness, ...
Posted by Michael Wonder on 23 Nov 2017
Roche’s Erivedge no longer funded by the NHS
23 November 2017 - Roche’s Erivedge will indeed no longer be funded on the National Health Service as a treatment ...
Posted by Michael Wonder on 21 Nov 2017
Is the NHS being taken for a ride on drug prices? We need to know
21 November 2017 - The competition watchdog is investigating, but we need a wider inquiry into pharmaceutical firms’ practices. ...
Posted by Michael Wonder on 20 Nov 2017
Bayer’s Stivarga wins NICE approval for GIST
20 November 2017 - Bayer’s Stivarga has been recommended by the National Institute for Health and Care Excellence as a ...